Spray dried solid dispersion of repaglinide using hypromellose acetate succinate: in vitro and in vivo characterization

References

• Ramachandran A, Snehalatha C, Viswanathan V, et al. Risk of noninsulin dependent diabetes mellitus conferred by obesity and central adiposity in different ethnic groups: a comparative analysis between Asian Indians, Mexican Americans and Whites. Diabetes Res Clin Pract. 1997;36(2):121–125.
   PubMed Web of Science ®Google Scholar
• Melmed S, Polonsky K, Larsen RP, et al. Williams textbook of endocrinology. 12th ed. Elsevier Health Sciences; Saunders; 2011. p. 1371–1435.
   Google Scholar
• Shi Y, Hu FB. The global implications of diabetes and cancer. The Lancet. 2014;383(9933):1947–1948.
   PubMed Web of Science ®Google Scholar
• Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.
   PubMed Web of Science ®Google Scholar
• Polonsky KS, Given BD, Hirsch LJ, et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318(19):1231–1239.
   PubMed Web of Science ®Google Scholar
• Manvi P, Narendra P, Bhaskar V. Preparation, characterization and in vitro evaluation of repaglinide binary solid dispersions with hydrophilic polymers. Int J Drug Dev Res. 2011;3:111–121.
   Google Scholar
• Wang LC, Fang FS, Gong YP, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. Medicine. 2018;97(38):e12476.
   PubMed Web of Science ®Google Scholar
• Ambavane V, Patil R, Ainapure SS. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. J Postgrad Med. 2002;48(3):246.
   PubMedGoogle Scholar
• Culy CR, Jarvis B. Repaglinide: a review of its theraprutic use in type 2 diabetes mellitus. Drugs. 2001;61(11):1625–1660.
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care. 1998;21(11):1897–1903.
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Dailey G, 3rd, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol. 2000;40(1):49–57.
   PubMed Web of Science ®Google Scholar
• Hatorp V. Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002 ;41(7):471–483.
   PubMed Web of Science ®Google Scholar
• Vemula VR, Lagishetty V, Lingala S. Solubility enhancement techniques. Int J Pharma Sci Rev Res. 2010;5(1):41–51.
   PubMedGoogle Scholar
• Shukla V. Techniques for solubility enhancement of poorly soluble drugs: an overview. J Med Pharma Allied Sci. 2012;1:18–38.
   Google Scholar
• Sareen S, Mathew G, Joseph L. Improvement in solubility of poor water-soluble drugs by solid dispersion. Int J Pharm Investig. 2012;2(1):12–17.
   PubMedGoogle Scholar
• Sosnik A, Seremeta KP. Advantages and challenges of the spray-drying technology for the production of pure drug particles and drug-loaded polymeric carriers. Adv Colloid Interface Sci. 2015;223:40–54.
   PubMed Web of Science ®Google Scholar
• Paudel A, Worku ZA, Meeus J, et al. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int J Pharm. 2013;453(1):253–284.
   PubMed Web of Science ®Google Scholar
• Official monograph for hypromellose acetate succinate. National Formulary (NF). 2006;25:1136–1138.
   Google Scholar
• Friesen DT, Shanker R, Crew M, et al. Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol Pharm. 2008;5(6):1003–1019.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xin T, Ye T, et al. Solid dispersion in the development of a nimodipine delayed-release tablet formulation. Asian J Pharm Sci. 2014;9(1):35–41.
   Google Scholar
• Tirucherai GS, Mitra AK. Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovir. AAPS PharmSciTech. 2003;4(3):124–135.
   Google Scholar
• Bolton S, Bon C. Pharmaceutical statistics pratical and clinical application. vol.135, 4th ed. 2004. New York (NY): M. Dekker.
   Google Scholar
• Shah SR, Parikh RH, Chavda JR, et al. Application of Plackett–Burman screening design for preparing glibenclamide nanoparticles for dissolution enhancement. Powder Technol. 2013;235:405–411.
   Web of Science ®Google Scholar
• Shah SR, Parikh RH, Chavda JR, et al. Glibenclamide nanocrystals for bioavailability enhancement: formulation design, process optimization, and pharmacodynamic evaluation. J Pharm Innov. 2014;9(3):227–237.
   Web of Science ®Google Scholar
• Alhalaweh A, Andersson S, Velaga SP. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci. 2009;38(3):206–214.
   PubMed Web of Science ®Google Scholar
• Quirk E, Doggett A, Bretnall A. Determination of residual acetone and acetone related impurities in drug product intermediates prepared as Spray Dried Dispersions (SDD) using gas chromatography with headspace autosampling (GCHS). J Pharm Biomed Anal. 2014;96:37–44.
   PubMed Web of Science ®Google Scholar
• Naik DR, Raval JP. Amorphous polymeric binary blend pH-responsive nanoparticles for dissolution enhancement of antiviral drug. J Saudi Chem Soc. 2016;20:S168–S177.
   Web of Science ®Google Scholar
• Ding X, Alani AWG, Robinson JR. Extended release and targeted drug delivery systems. In: Gennaro AR, editor. Remington: the science and practice of industrial pharmacy. 21st ed. Philadelphia (PA): Lippincott Williams and Wilkins; 2006. p. 940–993.
   Google Scholar
• Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol. 2006;5(1):9.
   PubMedGoogle Scholar
• Chatap VK, Patil SD. In-vitro and in-vivo consideration of repaglinide immediate-release tablet: assessment of porous acetostarch as a promising carrier for dissolution rate enhancement. Food Sci Technol. 2016;4(4):78–88.
   Google Scholar
• Rampal A, Singh M, Mahajan S, et al. Formulation and characterization of HPMC and HPMCAS based solid dispersions of fenofibrate: a comparative study. Int J App Pharm. 2019;11(4):41–48.
   Google Scholar
• Ambike AA, Mahadik KR, Paradkar A. Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm Res. 2005;22(6):990–998.
   PubMed Web of Science ®Google Scholar
• Yin LF, Huang SJ, Zhu CL, et al. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug Dev Ind Pharm. 2012;38(11):1371–1380.
   PubMed Web of Science ®Google Scholar
• Yang XD, Li WS, Tian YJ, et al. Dissolution rate enhancement of repaglinide by solid dispersion. Trop J Pharm Res. 2016;15(6):1123–1128.
   Web of Science ®Google Scholar